Asimov introduced its AAV Edge Stable Producer system, a platform generating stable HEK293 cell lines with integrated viral genes for adeno-associated virus (AAV) vector production, aiming to overcome limitations of transient transfection methods. This technology facilitates scalable, consistent, and cost-efficient manufacturing of AAV gene therapies. By obviating the need for multiple GMP plasmids every batch and enabling high titers (up to 6E15 vg/L), Asimov's system addresses key challenges in commercialization of gene therapies. CEO Alec Nielsen highlighted that the stable producer cells can reduce supply chain risks and batch variability, supporting safer and more effective treatments for severe diseases.